

Saturday, May 31, 2014

Session Title: Gastrointestinal (Noncolorectal) Cancer
Session Type: General Poster Session
Date: Saturday May 31
Time: 8:00 AM - 11:45 AM
Location: S Hall A2

NCIC CTG PA.3

A novel biomarker panel examining response to gemcitabine (G) with or without erlotinib (E) for pancreatic cancer (PA) therapy in NCIC clinical trials group PA.3 (Abstract #4133)

Authors: David Shultz, Jonathan Pai, Madeline Sydney Graber, Gregory M. Heestand, Daniel Tandel Chang, Wendy R. Parulekar, Dongsheng Tu, Malcolm J. Moore, Albert Koong

http://abstracts.asco.org/144/AbstView_144_132913.html

Session Title: Gastrointestinal (Colorectal) Cancer
Session Type: General Poster Session
Date: Saturday May 31
Time: 8:00 AM - 11:45 AM
Location: S Hall A2

NCIC CTG CO.23

The NCIC CTG and AGITG CO.23 trial: A phase III randomized study of BBI608 plus best supportive care (BSC) versus placebo (PBO) plus BSC in patients (Pts) with pretreated advanced colorectal carcinoma (CRC) (Abstract #TPS3660)

Authors: Derek J. Jonker, Louise M. Nott, Takayuki Yoshino, Chiang Li, Sharlene Gill, Jeremy David Shapiro, Atsushi Ohtsu, John Raymond Zalberg, Michael M. Vickers, John Simes, Alice Chia-chi Wei, Nicole Mittmann, Nadine M Magoski, Yvonne Murray, Eric Tsobanis, Dongsheng Tu, David Kerstein, Christopher J. O'Callaghan

http://abstracts.asco.org/144/AbstView_144_129760.html

Session Title: Gastrointestinal (Colorectal) Cancer
Session Type: General Poster Session
Date: Saturday May 31
Time: 8:00 AM - 11:45 AM
Location: S Hall A2

NCIC CTG CO.21

A phase III study of the impact of a physical activity program on disease-free survival in patients with high-risk stage II or stage III colon cancer: A randomized controlled trial (NCIC CTG CO.21) (Abstract #TPS3663)

Authors: Christopher M. Booth, Janette L. Vardy, Sharlene Gill, Derek J. Jonker, Christopher J. O'Callaghan, Christine Friedenreich, Ralph M. Meyer, Michael Brundage, Rebecca Wong, Haryana M. Dhillon, Patti O'Brien, Emma Goddard, Neil Sun Chua, Sasha Lipichuk, Michael Susmoy Sanatani, Philip James Beale, Stephen Begbie, Stephen P. Ackland, Dongsheng Tu, Kerry S. Courneya

http://abstracts.asco.org/144/AbstView_144_130398.html

Session Title: Tumor Biology
Session Type: General Poster Session
Date: Saturday May 31
Time: 1:15 PM - 5:00 PM
Location: S Hall A2

General Review

The association of treatment-emergent proteinuria (TEP) with baseline/treatment variables in patients (pts) treated with antiangiogenic tyrosine kinase inhibitors (AA-TKIs): A pooled analysis of NCIC Clinical Trial Group (NCIC CTG) trials (Abstract #11126)

Authors: Maria Bonomi (ASCO Merit Award Recipient), Hao Xu, Scott Andrew Laurie, Elizabeth A. Eisenhauer, Dongsheng Tu, Joseph L. Pater, Lesley Seymour, Penelope Ann Bradbury

http://abstracts.asco.org/144/AbstView_144_129279.html

Session Title: Breast Cancer - HER2/ER
Session Type: Oral Abstract Session
Date: Saturday May 31
Time: 3:00 PM - 6:00 PM
Location: N Hall B1

NCIC CTG MA.21

Prognostic associations of 25OH vitamin D in NCIC CTG MA.21, a phase III adjuvant RCT of three chemotherapy regimens (EC/T, CEF, AC/T) in high-risk breast cancer (BC) (Abstract #504)

Authors: Ana Elisa Lohmann, Judy-Anne W. Chapman, Margot J. Burnell, Mark Norman Levine, Elena Tsvetkova, Kathleen I. Pritchard, Karen A. Gelmon, Patti O'Brien, Lei Han, Hope S. Rugo, Kathy S. Albain, Edith A. Perez, Theodore A. Vandenberg, Haji I. Chalchal, Ravinder Pal Singh Sawhney, Lois E. Shepherd, Pamela Jean Goodwin

http://abstracts.asco.org/144/AbstView_144_128900.html

Sunday, June 1, 2014

Session Title: Cancer Prevention/Epidemiology
Session Type: General Poster Session
Date: Sunday June 1
Time: 8:00 AM - 11:45 AM
Location: S Hall A2

NCIC CTG HN.6

Cancer patients' acceptability of incorporating an epidemiology questionnaire within a clinical trial: A patient preference study and subanalysis of the NCIC clinical trials group HN.6 clinical trial (Abstract #1586)

Authors: Sinead Cuffe, Henrique Hon, Kimberly Tobros, Osvaldo Espin-Garcia, Yonathan Brhane, Luke Harland, Ehab Fadhel, Lawson Eng, Anthony LaDelfa, John N. Waldron, Bingshu E. Chen, Wei Xu, Christine E. Simmons, Zahra Kassam, Lillian L. Siu, Alexander Montenegro, Wendy R. Parulekar, Geoffrey Liu

http://abstracts.asco.org/144/AbstView_144_127556.html

Session Title: Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics
Session Type: General Poster Session
Date: Sunday June 1
Time: 8:00 AM - 11:45 AM
Location: S Hall A2

General Review

Correlation between phase 2 clinical trial design and subsequent phase 3 outcome (Abstract #2549)

Authors: Annette E. Hay, Jose Gerard Monzon, Gail T McDonald, Joseph L Pater, Ralph M. Meyer, Eric Xueyu Chen, Bingshu E. Chen, Janet Dancey

http://abstracts.asco.org/144/AbstView_144_126617.html

Session Title: Gastrointestinal (Noncolorectal) Cancer
Session Type: Poster Highlights Session
Date: Sunday June 1
Time 1: 8:00 AM - 11:00 AM
Location 1: S Hall A2
Time 2: 11:30 AM - 12:45 PM
Location 2: E Hall D2

NCIC CTG ES.2 (TROG 0301)

A randomized phase III study in advanced esophageal cancer (OC) to compare the quality of life (QoL) and palliation of dysphagia in patients treated with radiotherapy (RT) or chemoradiotherapy (CRT) (Abstract #4009)

Authors: Michael Gordon Penniment, Jennifer A Harvey, Rebecca Wong, Sonya Stephens, Heather-Jane Au, Christopher J. O'Callaghan, Andrew Kneebone, Sam Ngan, Iain G. Ward, Rajarshi Roy, Thomas Richard Sullivan, Tirath Nijjar, James Joseph Biagi, Liam A Mulroy

http://abstracts.asco.org/144/AbstView_144_135050.html

Session Title: Plenary Session Including the Science of Oncology Award and Lecture
Session Type: Plenary Session
Date: Sunday June 1
Time: 1:00 PM - 4:00 PM
Location: N Hall B1

NCIC CTG MAC.4 (IBCSG SOFT)/ NCIC CTG MAC.5 (IBCSG TEXT)

Randomized comparison of adjuvant aromatase inhibitor (AI) exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Joint analysis of IBCSG TEXT and SOFT trials (Abstract #LBA1)

Authors: Olivia Pagani, Meredith M. Regan, Barbara Walley, Gini F. Fleming, Marco Colleoni, Istvan Lang, Henry Leonidas Gomez, Carlo Tondini, Harold J. Burstein, Edith A. Perez, Eva Ciruelos, Vered Stearns, Herve R. Bonnefoi, Silvana Martino, Charles E. Geyer, Manuela Rabaglio-Poretti, Alan S. Coates, Richard D. Gelber, Aron Goldhirsch, Prudence A. Francis

http://abstracts.asco.org/144/AbstView_144_129398.html

Session Title: Plenary Session Including the Science of Oncology Award and Lecture
Session Type: Plenary Session
Date: Sunday June 1
Time: 1:00 PM - 4:00 PM
Location: N Hall B1

NCIC CTG MAC.13 (BIG 2-06; NCCTG [Alliance] N063D)

First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC) (Abstract #LBA4)

Authors: Martine J. Piccart-Gebhart, Andrew Peter Holmes, Jose Baselga, Evandro De Azambuja, Amylou C. Dueck, Giuseppe Viale, Jo Anne Zujewski, Aron Goldhirsch, Sergio Santillana, Kathleen I. Pritchard, Antonio C. Wolff, Christian Jackisch, Istvan Lang, Michael Untch, Ian E. Smith, Frances Boyle, Binghe Xu, Henry Leonidas Gomez, Richard D. Gelber, Edith A. Perez

http://abstracts.asco.org/144/AbstView_144_128258.html

Monday, June 2, 2014

Session Title: Breast Cancer - HER2/ER
Session Type: General Poster Session
Date: Monday June 2
Time: 8:00 AM - 11:45 AM
Location: S Hall A2

NCIC CTG MA.31

Lapatinib or trastuzumab with taxane therapy as first-line treatment in metastatic breast cancer (MBC): A biomarker analysis in NCIC CTG MA.31 (Abstract #601)

Authors: Wendy R. Parulekar, Samuel Aparicio, Judy-Anne W. Chapman, Dongxia Gao, Lois E. Shepherd, Frances M. Boyle, Bella Kaufman, Louise Yelle, Theodore A. Vandenberg, Muhammad Salim, Julie Lorette, Rocco J. Crescenzo, Liting Zhu, Yvonne Murray, David Huntsman, Karen A. Gelmon

http://abstracts.asco.org/144/AbstView_144_127259.html

Session Title: Breast Cancer - HER2/ER
Session Type: General Poster Session
Date: Monday June 2
Time: 8:00 AM - 11:45 AM
Location: S Hall A2

NCIC CTG MA.31

Effect of serum HER2, TIMP-1, and CAIX on outcome in HER2+ metastatic breast cancer patients treated in first line with lapatinib or trastuzumab combined with taxane: NCIC CTG MA.31 (Abstract #617)

Authors: Diep Ho, Jessica Huang, Judy-Anne W. Chapman, Kim Leitzel, Suhail M. Ali, Lois E. Shepherd, Wendy R. Parulekar, Catherine Elizabeth Ellis, Rocco J. Crescenzo, Liting Zhu, Shakeel Virk, Dora Nomikos, Samuel Aparicio, Karen A. Gelmon, Walter P. Carney, Allan Lipton

http://abstracts.asco.org/144/AbstView_144_130428.html

Session Title: Breast Cancer - HER2/ER
Session Type: General Poster Session
Date: Monday June 2
Time: 8:00 AM - 11:45 AM
Location: S Hall A2

NCIC CTG MAC.4 (IBCSG SOFT)/ NCIC CTG MAC.5 (IBCSG TEXT)

Patient-reported endocrine symptoms, sexual functioning, and quality of life (QoL) in the IBCSG TEXT and SOFT trials: Adjuvant treatment with exemestane (E) plus ovarian function suppression (OFS) versus tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC) (Abstract #557)

Authors: Juerg Bernhard, Weixiu Luo, Karin Ribbi, Marco Colleoni, Harold J. Burstein, Carlo Tondini, Graziella Pinotti, Simon Spazzapan, Thomas Ruhstaller, Fabio Puglisi, Lorenzo Pavesi, Vani Parmar, Meredith M. Regan, Olivia Pagani, Gini F. Fleming, Prudence A. Francis, Alan S. Coates, Richard D. Gelber, Aron Goldhirsch, Barbara Walley

http://abstracts.asco.org/144/AbstView_144_129713.html

Session Title: Breast Cancer - HER2/ER
Session Type: General Poster Session
Date: Monday June 2
Time: 8:00 AM - 11:45 AM
Location: S Hall A2

NCIC CTG MA.32

Vitamin B12 (Vit B12) biochemical (BCH) deficiency (DEF) in non-diabetic breast cancer (BC) patients on NCIC CTG MA.32: A phase III randomized adjuvant BC trial comparing metformin (Met) to placebo (PI) (Abstract #542)

Authors: Mira F. Liebman, William Brien, Wendy R. Parulekar, Karen A. Gelmon, Lois E. Shepherd, Jennifer A. Ligibel, Dawn L. Hershman, Priya Rastogi, Ingrid A. Mayer, Timothy J. Hobday, Julie Lemieux, Alastair Mark Thompson, Kathleen I. Pritchard, Timothy Joseph Whelan, Som Mukherjee, Haji I. Chalchal, Vanessa Bernstein, Vuk Stambolic, Bingshu E. Chen, Pamela Jean Goodwin

http://abstracts.asco.org/144/AbstView_144_127505.html

Session Title: Breast Cancer - HER2/ER
Session Type: General Poster Session
Date: Monday June 2
Time: 8:00 AM - 11:45 AM
Location: S Hall A2

NCIC CTG MAC.9

SWOG S0307 phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: Comparison of toxicities and patient-stated preference for oral versus intravenous delivery. (Abstract #558)

Authors: Julie Gralow, William E. Barlow, Alexander H. G. Paterson, Danika Lew, Alison Stopeck, Daniel F. Hayes, Dawn L. Hershman, Mark Schubert, Mark Clemons, Catherine H. Van Poznak, Elizabeth Claire Dees, James N. Ingle, Carla Isadora Falkson, Anthony D. Elias, Michael J. Messino, Jeffrey H. Margolis, Shaker R. Dakhil, Helen K. Chew, Robert B. Livingston, Gabriel N. Hortobagyi

http://abstracts.asco.org/144/AbstView_144_129741.html

Session Title: Tumor Biology
Session Type: Poster Highlights Session
Date: Monday June 2
Time 1: 8:00 AM - 11:00 AM
Location 1: S405
Time 2: 11:30 AM - 12:45 PM
Location 2: S406

NCIC CTG MA.21

Prognostic and predictive significance of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial (Abstract #11019)

Authors: Karen A. Gelmon, Judy-Anne W. Chapman, Shuzhen Liu, Margot J. Burnell, Mark Norman Levine, Kathleen I. Pritchard, Timothy Joseph Whelan, Hope S. Rugo, Kathy S. Albain, Edith A. Perez, Shakeel Virk, Patti O'Brien, Lois E. Shepherd, Torsten O. Nielsen

http://abstracts.asco.org/144/AbstView_144_131686.html

Session Title: Breast Cancer - HER2/ER
Session Type: General Poster Session
Date: Monday June 2
Time: 8:00 AM - 11:45 AM
Location: S Hall A2

General Review

Competing risks of mortality by PAM50 intrinsic subtype: BC tamoxifen-treated cohort (Abstract #562)

Authors: Judy-Anne W. Chapman, Shuzhen Liu, Samuel Leung, Torsten O. Nielsen

http://abstracts.asco.org/144/AbstView_144_129910.html

Session Title: Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy
Session Type: General Poster Session
Date: Monday June 2
Time: 8:00 AM - 11:45 AM
Location: S Hall A2

NCIC CTG MA.21

Outcomes of 3-weekly doxorubicin and cyclophosphamide followed by paclitaxel (AC/T) in a randomized trial (RCT) compared to a case-control matched British Columbia (BC) breast cancer population (Abstract #1037)

Authors: Sheridan Marie Wilson, Yvonne Zheng, Judy-Anne W. Chapman, Margot J. Burnell, Caroline Speers, Emily Baxter, Scott Tyldesley, Lois E. Shepherd, Karen A. Gelmon, Caroline A. Lohrisch

http://abstracts.asco.org/144/AbstView_144_126836.html

Session Title: Cancer Prevention/Epidemiology
Session Type: Poster Highlights Session
Date: Monday June 2
Time 1: 1:15 PM - 4:15 PM
Location 1: S102
Time 2: 4:45 PM - 6:00 PM
Location 2: S100a

NCIC CTG MA.12

Pharmacokinetic analysis of tamoxifen metabolites in premenopausal women with early breast cancer: A substudy of NCIC CTG MA.12 randomized clinical trial (Abstract #1524)

Authors: Shahbal Bill Kangarloo, Ella S.M. Ng, Vivien H.C. Bramwell, Kathleen I. Pritchard, Lois E. Shepherd, Dongsheng Tu, Anthony M. Magliocco, Patricia A. Tang

http://abstracts.asco.org/144/AbstView_144_125612.html

Session Title: Health Services Research
Session Type: General Poster Session
Date: Monday June 2
Time: 1:15 PM - 5:00 PM
Location: S Hall A2

General Review

Improving cancer clinical trial accrual in Ontario, Canada: The clinical trials infrastructure fund (CTIF) experience (Abstract #6602)

Authors: Lesleigh S. Abbott, Joseph L Pater, Kay T. Friel, Diana Kato, Janet Dancey

http://abstracts.asco.org/144/AbstView_144_129298.html

Session Title: Health Services Research
Session Type: General Poster Session
Date: Monday June 2
Time: 1:15 PM - 5:00 PM
Location: S Hall A2

General Review

Accrual of adolescents and young adults with cancer to eligible clinical trials: A report from the NCIC Clinical Trials Group (NCIC CTG) (Abstract #6543)

Authors: Lesleigh S. Abbott (ASCO Merit Award Recipient), Annette E. Hay, Corey Willman, Alison Urton, Joseph L Pater, Janet Dancey

http://abstracts.asco.org/144/AbstView_144_129269.html

Session Title: Lymphoma and Plasma Cell Disorders
Session Type: General Poster Session
Date: Monday June 2
Time: 1:15 PM - 5:00 PM
Location: S Hall A2

NCIC CTG MY.10

A randomized phase 3 trial of thalidomide and prednisone (TP) as maintenance therapy following autologous stem cell transplantation (ASCT) in patients with multiple myeloma (MM): An updated analysis of the NCIC Clinical Trials Group MY10 trial (Abstract #8591)

Authors: Annette E. Hay, Suzanne Trudel, Nizar J. Bahlis, Darrell White, Waleed Sabry, Andrew Belch, Tony J. Reiman, Jean Roy, Chaim Shustik, Michael J. Kovacs, Jonathan Sussman, Donna Ellen Reece, Martha Lacy, Ralph M. Meyer, Lois E. Shepherd, Kate Whelan, Liting Zhu, Judy-Anne W. Chapman, A. Keith Stewart

http://abstracts.asco.org/144/AbstView_144_127625.html

Session Title: Health Services Research
Session Type: General Poster Session
Date: Monday June 2
Time: 1:15 PM - 5:00 PM
Location: S Hall A2

General Review

Estimation of drug cost avoidance (DCA) and pathology cost avoidance (PCA) through participation in NCIC clinical trials group (NCIC-CTG) phase III clinical trials in Canada (Abstract #6560)

Authors: Patricia A. Tang, Annette E. Hay, Christopher J. O'Callaghan, Nicole Mittmann, Carole Chambers, Joseph L Pater, Natasha B. Leighl

http://abstracts.asco.org/144/AbstView_144_131772.html

Session Title: Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy
Session Type: Poster Highlights Session
Date: Monday June 2
Time 1: 1:15 PM - 4:15 PM
Location 1: E354b
Time 2: 4:45 PM - 6:00 PM
Location 2: E Hall D1

NCIC CTG MAC.11 (SWOG 0221)

Outcome of male patients and black patients enrolled in S0221, an intergroup chemotherapy study (Abstract #1016)

Authors: G. Thomas Budd, William E. Barlow, Halle C. F. Moore, Timothy J. Hobday, James A. Stewart, Claudine Isaacs, Muhammad Salim, Jonathan K. Cho, Kathy S. Albain, Kristine Rinn, Helen K. Chew, Gary Von Burton, Timothy David Moore, Gordan Srkalovic, Bradley Alexander McGregor, Lawrence E. Flaherty, Robert B. Livingston, Danika Lew, Julie Gralow, Gabriel N. Hortobagyi

http://abstracts.asco.org/144/AbstView_144_128157.html

Tuesday, June 3, 2014

Session Title: Health Services Research
Session Type: Poster Highlights Session
Date: Tuesday June 3
Time 1: 8:00 AM - 11:45 AM
Location 1: E354b
Time 2: 11:30 AM - 12:45 PM
Location 2: E253

General Review

The use of health-related quality of life outcomes in oncology practice: An international study. (Abstract #6524)

Authors: Julie Rouette, Jane M. Blazeby, Madeleine King, Melanie Calvert, Yingwei Peng, Ralph M. Meyer, Jolie Ringash, Melanie Walker, Michael Donald Brundage

http://abstracts.asco.org/144/AbstView_144_134362.html

Session Title: Lung Cancer - Non-small Cell Metastatic
Session Type: Poster Highlights Session
Date: Tuesday June 3
Time 1: 8:00 AM - 11:45 AM
Location 1: E354b
Time 2: 11:30 AM - 12:45 PM
Location 2: E450

BR.26

NCIC CTG BR.26: A phase III randomized, double blind, placebo controlled trial of dacomitinib versus placebo in patients with advanced/metastatic non-small cell lung cancer (NSCLC) who received prior chemotherapy and an EGFR TKI. (Abstract #8036^)

Authors: Peter Michael Ellis, Geoffrey Liu, Michael Millward, Francesco Perrone, Frances A. Shepherd, Sophie Sun, Byoung Chul Cho, Alessandro Morabito, Martin R. Stockler, Rafal Wierzbicki, Victor Cohen, Normand Blais, Randeep S. Sangha, Adolfo G. Favaretto, Jin Hyoung Kang, Carolyn F. Wilson, Joseph O'Connell, Keyue Ding, Glenwood D. Goss, Penelope Ann Bradbury

http://abstracts.asco.org/144/AbstView_144_132768.html
